Visit the Aurora Cannabis Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.
Mr. Battley Appointed to Board of Directors of MedReleaf Australia
TSX | NYSE: ACB
EDMONTON, Dec. 21, 2019 /PRNewswire/ – Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE │ TSX: ACB), the Canadian company defining the future of cannabis worldwide, announces a change to the Executive Team. Cam Battley has stepped down as Chief Corporate Officer effective December 20, 2019.
Mr. Battley joined Aurora in 2016, serving a number of senior roles critical to the success of the company in its early years before being named Chief Corporate Officer in 2018. Mr. Battley has been instrumental in Aurora’s international growth, serving as a powerful advocate and corporate voice in support of global acceptance.
Mr. Battley has earned the reputation as a formidable leader and advocate in Canada and beyond. With a clear passion for cannabis advocacy, Aurora is grateful for his contributions to the company’s growth and role as a global medical cannabis leader. As the Canadian cannabis industry evolves, Aurora continues to enhance its executive team to be fit for the longevity of the industry in Canada and beyond.
Our roots run deep, and Cam has been an integral part of the development, growth and expansion of Aurora. We are grateful for Cam’s leadership and passion over his many years with Aurora. I am sure Cam will be successful as he moves on to tackle Australia.
Terry Booth, CEO of Aurora
Mr. Battley was appointed to MedReleaf Australia’s Board in November of 2019. This appointment has been approved by Australia’s Federal Office of Drug Control. MedReleaf Australia is a privately held medical cannabis company established in 2016, based in Brisbane, Queensland. MedReleaf Australia is fully licensed to cultivate, manufacture, import and sell medical cannabis. Aurora holds a 10% stake as well as 50% voting rights in MedReleaf Australia. Australia has seen dramatic growth in the medical cannabis space over the last 18 months from less than 500 patients in June of 2018 to over 24,000 as of November 2019.
Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 625,000 kg per annum and sales and operations in 25 countries across five continents, Aurora is one of the world’s largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.
Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high-quality consistent product. Designed to be replicable and scalable globally, our production facilities are designed to produce cannabis at significant scale, with high quality, industry-leading yields, and low-per gram production costs. Each of Aurora’s facilities is built to meet European Union Good Manufacturing Practices (“EU GMP”) standards. Certification has been granted to Aurora’s first production facility in Mountain View County, the MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland. All Aurora facilities are designed and built to the EU GMP standard.
In addition to the Company’s rapid organic growth and strong execution on strategic M&A, which to date includes 17 wholly owned subsidiary companies – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs, Whistler, Chemi Pharmaceutical, and Hempco – Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), CTT Pharmaceuticals (OTCC: CTTH), Alcanna Inc. (TSX: CLIQ), High Tide Inc. (CSE: HITI), EnWave Corporation (TSXV: ENW), Capcium Inc. (private), Evio Beauty Group (private). Aurora’s Common Shares trade on the TSX and NYSE under the symbol “ACB”, and is a constituent of the S&P/TSX Composite Index.
For more information about Aurora, please visit our investor website, investor.auroramj.com
For fact-based information on Aurora Cannabis, view the company’s sponsored Investor Dashboard.
Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.